Patents Assigned to Genentech
  • Patent number: 9234024
    Abstract: The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: January 12, 2016
    Assignee: GENENTECH, INC.
    Inventors: Sachdev S. Sidhu, Bing Li, Menno Van Lookeren Campagne, Christian Wiesmann
  • Publication number: 20160002228
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: July 16, 2015
    Publication date: January 7, 2016
    Applicant: Genentech, Inc.
    Inventors: Anthony ESTRADA, Wen Liu, Snahel Patel, Michael Siu
  • Publication number: 20160002593
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Application
    Filed: September 11, 2015
    Publication date: January 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
  • Publication number: 20160000910
    Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20160002266
    Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 7, 2016
    Applicants: GENENTECH, INC., FORMA TM, LLC
    Inventors: Kenneth W BAIR, Timm R BAUMEISTER, Peter DRAGOVICH, Xiongcai LIU, Snahel PATEL, Po-Wai YUEN, Mark ZAK, Guiling ZHAO, Yamin ZHANG, Xiaozhang ZHENG
  • Publication number: 20160002121
    Abstract: Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [125I] HIP-DOTA label reagent 6 is prepared by an efficient and convenient process.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Charles Andrew Boswell, Leslie A. Khawli, Jan Marik, Simon Williams
  • Patent number: 9226961
    Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: January 5, 2016
    Assignee: Genentech, Inc.
    Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
  • Publication number: 20150376283
    Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Applicant: GENENTECH, INC.
    Inventors: Junichiro Sonoda, Yan Wu
  • Publication number: 20150376272
    Abstract: The present invention relates generally to the inhibition of tumor angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis and the suppression of tumor growth in tumors refractory to an anti-vascular endothelial growth factor (VEGF) treatment, using IL-17 antagonists, such as anti-IL-17 antibodies and other antagonists.
    Type: Application
    Filed: January 16, 2015
    Publication date: December 31, 2015
    Applicant: GENENTECH, INC.
    Inventors: Alicia Chung, Napoleone Ferrara
  • Publication number: 20150376570
    Abstract: The present invention relates to methods and compositions for use in generating induced hepatocytes by reprogramming non-hepatocyte cells.
    Type: Application
    Filed: April 2, 2015
    Publication date: December 31, 2015
    Applicant: GENENTECH, INC.
    Inventors: Kamen P. Simeonov, Hirdesh Uppal
  • Publication number: 20150376265
    Abstract: The invention provides compositions comprising anti-gH antibodies and anti-Complex I antibodies as well as methods of using the same.
    Type: Application
    Filed: December 19, 2014
    Publication date: December 31, 2015
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Becket L. Feierbach, Ashley Fouts, Isidro Hotzel, Bing Li, Jo-Anne S. Hongo, Rajesh Vij
  • Patent number: 9221813
    Abstract: The invention provides intermediates and processes of preparation thereof useful in the preparation of compounds that can be used as CHK1 inhibitors.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: December 29, 2015
    Assignee: Genentech, Inc.
    Inventor: Chong Han
  • Patent number: 9221900
    Abstract: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: December 29, 2015
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Andreas Muhs, Oskar Adolfsson, Ryan J. Watts
  • Publication number: 20150366985
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 24, 2015
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20150368358
    Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.
    Type: Application
    Filed: March 26, 2015
    Publication date: December 24, 2015
    Applicant: GENENTECH, INC.
    Inventor: Luc Desnoyers
  • Publication number: 20150368244
    Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 24, 2015
    Applicant: Genentech, Inc.
    Inventors: Hazel Joan Dyke, Emanuela Gancia, Lewis J. Gazzard, Simon Charles Goodacre, Joseph P. Lyssikatos, Calum MacLeod, Karen Williams, Huifen Chen
  • Patent number: 9216980
    Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • Patent number: 9216988
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Olivier Rene
  • Publication number: 20150361392
    Abstract: Provided herein is a method of culturing epithelial stem cells and tissue fragments comprising epithelial stem cells in liquid cultures.
    Type: Application
    Filed: August 25, 2015
    Publication date: December 17, 2015
    Applicant: GENENTECH, INC.
    Inventor: Brian Biehs
  • Publication number: 20150361184
    Abstract: The invention provides for methods of decreasing dual leucine zipper kinase (DLK) stability in a neuron, or decreasing or inhibiting the phosphorylation of certain amino acid residues of DLK, comprising administering to a neuron, or portion thereof, an agent which decreases or inhibits the phosphorylation of DLK and decreases the stability of DLK as well as methods for inhibiting or preventing neuronal degeneration in a patient by administering to a patient an agent which inhibits phosphorylation of dual leucine zipper kinase (DLK).
    Type: Application
    Filed: August 28, 2015
    Publication date: December 17, 2015
    Applicant: GENENTECH, INC.
    Inventors: Daisy BUSTOS, Sarah HUNTWORK-RODRIGUEZ, Donald KIRKPATRICK, Joseph Wesley LEWCOCK, Arundhati Sengupta GHOSH